학술논문
PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
Document Type
article
Author
Sanjal H. Desai; Levi Pederson; Betsy LaPlant; Raphael Mwangi; Matthew Maurer; Jason R. Young; William R. Macon; Rebecca L. King; Yucai Wang; James R. Cerhan; Andrew Feldman; David J. Inwards; Ivana Micallef; Patrick Johnston; Luis F. Porrata; Stephen M. Ansell; Thomas M. Habermann; Thomas E. Witzig; Grzegorz S. Nowakowski
Source
Blood Cancer Journal, Vol 12, Iss 5, Pp 1-6 (2022)
Subject
Language
English
ISSN
2044-5385
Abstract
Abstract Studies evaluating Positron Emission Tomography scan after 2 cycles of chemotherapy (PET2) in newly diagnosed diffuse large B cell lymphoma (DLBCL) are heterogeneous in patient characteristics, treatments and have conflicting results. Here we report association of PET2 with outcomes in two large independent prospective cohorts of newly diagnosed DLBCL pts treated with two RCHOP-based regimens. The discovery cohort consisted of pts enrolled in single arm phase 2 MC078E study of lenalidomide with RCHOP (R2CHOP). The validation cohort consisted of RCHOP-treated pts from the Molecular Epidemiology Resource (MER) cohort. Pts who received 3-6 cycles of therapy and had PET2 were included in the study. Patients who progressed on PET2 were excluded. Revised response criteria 2007 were used to define PET2 response PET2 positive (PET2 + ) pts had inferior EFS [24-month EFS 45.5% vs 87.9%, HR 4.0, CI95 (2.1–7.9), p